Alendronate in adults with CF related osteoporosis
Funding for this trial has been provided in full or in part by Cystic Fibrosis Foundation Therapeutics, Inc.
Number of Participants Being Recruited:
Single / Multi-Center:
STUDY BACKGROUND INFORMATION:
This study is enrolling male and females with Cystic Fibrosis and low bone density ages 18 to 45 years of age. Some participants will receive calcium and Vitamin D supplements with a placebo daily for one month. Other participants will receive calcium and Vitamin D supplements with oral alendronate daily for one month. Treatment continues if differences are seen in bone mineral density between the treatment arms. Participants are followed for biochemical response at week 6, 12, and 52. Bone mineral density is measured at 1 year and 2 years.
>= 18 Years
20 - 90 Percent Predicted
P. aeruginosa status:
B. cepacia status:
Other Primary Eligibility Requirements:
Note: Detailed eligibility criteria information may be available on clinicaltrials.gov. If a specific
trial listing for this trial is available, a link to the specific clinicaltrials.gov listing will be present in the "More Information" section below.
The sites listed below are currently recruiting subjects. Please note that this list generally lists either the pediatric or adult program but not both even though both programs may be recruiting subjects. Also, this list does not include sites that may be participating in the study but are not yet open for recruitment. If you are interested in this study please contact your center for more information.
University of North Carolina at Chapel Hill (Adult), Chapel Hill, NC, 27599
Shive, Nadia Phone: (919) 966-9198 Email: email@example.com